VistaPharm – Recall of sucralfate oral suspension

- On September 22, 2023, VistaPharm announced a consumer-level recall of one lot of sucralfate oral suspension 1 gram/10 mL due to *Bacillus cereus* contamination in the product.
    - Other sucralfate products that are not being recalled are available for patients to use.
- The recalled lots were distributed nationwide.

Product Description	NDC#	Lot # (Expiration Date)
Sucralfate oral suspension 1 gram/10 mL in 16 oz (414 mL)	66689-305-16	810300 (10/31/2023)

- Sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.
- In the population most at risk, the immunocompromised population, there is a reasonable probability that microbial contamination of the oral suspension can result in disseminated, life threatening infections such as endocarditis and necrotizing soft tissue infections.
- To date, VistaPharm has not received any reports of adverse events related to this recall.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- For any questions regarding this recall, contact Inmar (contractor for VistaPharm) by phone at **1-800-967-5952** or by email at rxrecalls@Inmar.com.